HUE059818T2 - Szenfetrinem vagy annak sója vagy észtere a mikrobakteriális fertõzés kezelésében való felhasználásra - Google Patents

Szenfetrinem vagy annak sója vagy észtere a mikrobakteriális fertõzés kezelésében való felhasználásra

Info

Publication number
HUE059818T2
HUE059818T2 HUE18721053A HUE18721053A HUE059818T2 HU E059818 T2 HUE059818 T2 HU E059818T2 HU E18721053 A HUE18721053 A HU E18721053A HU E18721053 A HUE18721053 A HU E18721053A HU E059818 T2 HUE059818 T2 HU E059818T2
Authority
HU
Hungary
Prior art keywords
sanfetrinem
ester
salt
mycobacterial infection
treating mycobacterial
Prior art date
Application number
HUE18721053A
Other languages
English (en)
Hungarian (hu)
Inventor
Aguirre David Barros
Robert H Bates
Del Rio Ruben Gonzalez
Losana Alfonso Mendoza
Garcia Santiago Ramon
Original Assignee
Glaxosmithkline Intellectual Property Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Dev filed Critical Glaxosmithkline Intellectual Property Dev
Publication of HUE059818T2 publication Critical patent/HUE059818T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D463/00—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D463/10—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D463/12—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals attached in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE18721053A 2017-05-08 2018-05-04 Szenfetrinem vagy annak sója vagy észtere a mikrobakteriális fertõzés kezelésében való felhasználásra HUE059818T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17382255 2017-05-08

Publications (1)

Publication Number Publication Date
HUE059818T2 true HUE059818T2 (hu) 2022-12-28

Family

ID=58709903

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18721053A HUE059818T2 (hu) 2017-05-08 2018-05-04 Szenfetrinem vagy annak sója vagy észtere a mikrobakteriális fertõzés kezelésében való felhasználásra

Country Status (22)

Country Link
US (1) US11253500B2 (enExample)
EP (1) EP3621609B1 (enExample)
JP (1) JP7123074B2 (enExample)
KR (1) KR102575872B1 (enExample)
CN (1) CN110869016B (enExample)
AU (1) AU2018265192B2 (enExample)
BR (1) BR112019023322B1 (enExample)
CA (1) CA3060396A1 (enExample)
CY (1) CY1125546T1 (enExample)
DK (1) DK3621609T3 (enExample)
ES (1) ES2925215T3 (enExample)
HR (1) HRP20221212T1 (enExample)
HU (1) HUE059818T2 (enExample)
LT (1) LT3621609T (enExample)
PL (1) PL3621609T3 (enExample)
PT (1) PT3621609T (enExample)
RS (1) RS63461B1 (enExample)
RU (1) RU2757272C2 (enExample)
SI (1) SI3621609T1 (enExample)
SM (1) SMT202200400T1 (enExample)
WO (1) WO2018206466A1 (enExample)
ZA (1) ZA201906810B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111184718A (zh) * 2018-11-15 2020-05-22 鲁南制药集团股份有限公司 法罗培南在制备治疗初治病原学阳性肺结核药物中的用途
CA3206024A1 (en) * 2021-02-01 2022-08-04 The Global Alliance For Tb Drug Development, Inc. Pretomanid amorphous form
CN117462551B (zh) * 2023-12-27 2024-05-17 深圳国家感染性疾病临床医学研究中心 茚地那韦和/或其衍生物在制备抗结核药物中的应用
CN122124048B (zh) * 2026-05-06 2026-07-24 深圳国家感染性疾病临床医学研究中心 埃替拉韦在制备结核分枝杆菌或非结核分枝杆菌的抑制剂中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ435990A3 (cs) 1989-09-08 1999-11-17 Glaxo S.P.A. Kyselina 10-(1-hydroxyethyl)-11-oxo-1-azatricyklo/7,2,0,03,8/-undec-2en-2-karboxylová a její deriváty, způsob jejich výroby, použití pro výrobu farmaceutických prostředků a farmaceutické prostředky s jejich obsahem
CA2067741C (en) 1990-08-21 2002-01-01 Alcide Perboni 10(1-hydroxyethly)-11-oxo-1-azatricyclo[7.2.0.0.3.8]undec-2-ene-2-carboxylic acid esters and a process for preparing thereof
GB9018330D0 (en) 1990-08-21 1990-10-03 Glaxo Spa Heterocyclic compounds
GB9104769D0 (en) 1991-03-07 1991-04-17 Glaxo Spa Heterocyclic compounds
GB9305813D0 (en) 1993-03-20 1993-05-05 Glaxo Spa Chemical process
EP2085084A1 (en) * 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics
EP2135871A1 (en) 2008-06-18 2009-12-23 LEK Pharmaceuticals D.D. New trinem antibiotics and inhibitors of beta-lactamases
WO2016046845A1 (en) 2014-09-25 2016-03-31 Manu Chaudhary Stealth, targeted nanoparticles (stn) for oral drug delivery
MA41495A (fr) 2015-02-12 2017-12-19 Anacor Pharmaceuticals Inc Composés benzoxaborole et leurs utilisations

Also Published As

Publication number Publication date
EP3621609B1 (en) 2022-07-27
KR20200003816A (ko) 2020-01-10
KR102575872B1 (ko) 2023-09-08
JP7123074B2 (ja) 2022-08-22
WO2018206466A1 (en) 2018-11-15
JP2020519592A (ja) 2020-07-02
BR112019023322B1 (pt) 2023-11-14
RS63461B1 (sr) 2022-08-31
HRP20221212T1 (hr) 2022-12-09
DK3621609T3 (da) 2022-08-29
EP3621609A1 (en) 2020-03-18
ZA201906810B (en) 2021-03-31
BR112019023322A2 (pt) 2020-06-16
ES2925215T3 (es) 2022-10-14
SMT202200400T1 (it) 2022-11-18
LT3621609T (lt) 2022-10-10
RU2019139864A3 (enExample) 2021-06-28
SI3621609T1 (sl) 2022-10-28
CY1125546T1 (el) 2026-02-25
US11253500B2 (en) 2022-02-22
AU2018265192B2 (en) 2021-06-17
RU2757272C2 (ru) 2021-10-12
CN110869016B (zh) 2023-09-12
CN110869016A (zh) 2020-03-06
RU2019139864A (ru) 2021-06-09
PT3621609T (pt) 2022-08-24
AU2018265192A1 (en) 2019-11-07
PL3621609T3 (pl) 2022-11-14
CA3060396A1 (en) 2018-11-15
US20200289462A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
IL258972A (en) Thin and flexible absorbent items
IL258962A (en) Thin and flexible absorbent items
IL258963A (en) Thin and flexible absorbent items
EP3137148A4 (en) Elongate steerable devices for insertion into a subject's body
SG11202000549TA (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
PL3271413T3 (pl) Kwasy estryfikowane do stosowania w materiałach polimerowych
HUE071527T2 (hu) Tradipitant gasztroparézis kezelésében történõ alkalmazásra
ZA201906810B (en) Sanfetrinem or a salt or ester thereof for use in treating mycobacterial infection
HUE069180T2 (hu) Adaptálható nedvszívó termék
SG11202102160VA (en) Markers useful in enrichment strategies for the treatment of osteoarthritis
HUE069615T2 (hu) Adaptálható nedvszívó termék
GB2581054B (en) Absorbent article
IL272658A (en) surface treatment
SMT202200221T1 (it) Medicinale per l'uso nel trattamento della gotta
GB2592518B (en) Absorbent article
PL3349594T3 (pl) Kompozycja zastępująca sól i jej zastosowanie
GB202017373D0 (en) Absorbent article
GB202110376D0 (en) Absorbent article
GB2585811B (en) Absorbent article
GB2593298B (en) Absorbent article
CA186508S (en) Absorbent article
CA186507S (en) Absorbent article
GB201412638D0 (en) Artist's implement
GB201405816D0 (en) Flexible "Dry-erase" mat
GB201413568D0 (en) Functionalised biologically active surface